BCD-281 vs Ublituximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: CD20 · full Multiple Sclerosis pipeline

BCD-281

Developed by Biocad

Phase 3 in Multiple Sclerosismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2028 · NCT07321093 (registry estimate)

No aligned efficacy figure on record for this race.

Ublituximab · Briumvi

Marketed by TG THERAPEUTICS, INC. and partners

Approved in Multiple Sclerosismonoclonal antibody
Reliable signal

NCT03277261 · Phase 3 · completed

This was a randomized, quadruple-masked, active-controlled trial of 549 participants, with ublituximab and teriflunomide administered alongside matching placebos. The primary clinical endpoint was met: ublituximab produced a significantly lower annualized relapse rate than teriflunomide through 96 weeks (p<0.0001).

Next expected readout: January 2027 · NCT05877963 (registry estimate)

Reported efficacy

Annualized Relapse Rate (ARR) (Up to 96 weeks): Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) (met)

Result source: NCT03277248

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCD-281Ublituximab
Annualised relapse rate—Trial running · NCT073210930.1 vs 0.2vs Teriflunomidewk 96 · n 271NCT03277261
1 other result
  • 0.1 vs 0.2 wk 96 · n 272 · Phase 3 · primary NCT03277248
Free of 3-month confirmed disability progression (%)—Trial running · NCT07321093—Trial running · NCT07220252
New or enlarging T2 lesions—Trial running · NCT07321093—Trial running · NCT07220252

Annualised relapse rate

BCD-281
—Trial running · NCT07321093
Ublituximab
0.1 vs 0.2vs Teriflunomidewk 96 · n 271NCT03277261
1 other result
  • 0.1 vs 0.2 wk 96 · n 272 · Phase 3 · primary NCT03277248

Free of 3-month confirmed disability progression (%)

BCD-281
—Trial running · NCT07321093
Ublituximab
—Trial running · NCT07220252

New or enlarging T2 lesions

BCD-281
—Trial running · NCT07321093
Ublituximab
—Trial running · NCT07220252
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BCD-281: no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BCD-281: 0 of 4 rows · Ublituximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricUblituximab
Dropout rate
12.4%a
NCT03277261 · Phase 3 · combination
show 7 more results
6.6%
NCT03277248 · Phase 3 · combination
0%Cohort 1
NCT02738775 · Phase 2 · registry result, not featured evidence
25%Cohort 2
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 3
NCT02738775 · Phase 2 · registry result, not featured evidence
11.1%Cohort 4
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 5
NCT02738775 · Phase 2 · registry result, not featured evidence
12.5%Cohort 6
NCT02738775 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
6.2%a
NCT03277261 · Phase 3 · combination
show 7 more results
1.1%
NCT03277248 · Phase 3 · combination
0%Cohort 1
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 2
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 3
NCT02738775 · Phase 2 · registry result, not featured evidence
11.1%Cohort 4
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 5
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 6
NCT02738775 · Phase 2 · registry result, not featured evidence
Serious AEs
11.4%a
NCT03277261 · Phase 3 · combination
show 7 more results
10.3%
NCT03277248 · Phase 3 · combination
0%Cohort 1
NCT02738775 · Phase 2 · registry result, not featured evidence
12.5%Cohort 2
NCT02738775 · Phase 2 · registry result, not featured evidence
25%Cohort 3
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 4
NCT02738775 · Phase 2 · registry result, not featured evidence
0%Cohort 5
NCT02738775 · Phase 2 · registry result, not featured evidence
25%Cohort 6
NCT02738775 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
headache 30.8%
pyrexia 15%
nasopharyngitis 12.5%
NCT03277261 · Phase 3 · combination
show 7 more results
headache 37.9%
nasopharyngitis 24.6%
back pain 12.9%
NCT03277248 · Phase 3 · combination
back pain 37.5% (placebo 0%)
headache 25% (placebo 15.4%)
hypoaesthesia 25% (placebo 7.7%)
NCT02738775 · Phase 2 · registry result, not featured evidence
dizziness 37.5% (placebo 23.1%)
fatigue 37.5% (placebo 38.5%)
headache 37.5% (placebo 15.4%)
NCT02738775 · Phase 2 · registry result, not featured evidence
arthralgia 25% (placebo 7.7%)
diarrhoea 25% (placebo 0%)
fatigue 25% (placebo 38.5%)
NCT02738775 · Phase 2 · registry result, not featured evidence
fatigue 50% (placebo 38.5%)
nasopharyngitis 37.5% (placebo 0%)
sinusitis 37.5% (placebo 15.4%)
NCT02738775 · Phase 2 · registry result, not featured evidence
dysphagia 37.5% (placebo 15.4%)
infusion related reaction 37.5% (placebo 23.1%)
throat irritation 37.5% (placebo 15.4%)
NCT02738775 · Phase 2 · registry result, not featured evidence
nausea 62.5% (placebo 15.4%)
dizziness 37.5% (placebo 23.1%)
fatigue 37.5% (placebo 38.5%)
NCT02738775 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ublituximab

Annualized Relapse 0.076 vs 0.188 Teriflunomide per year @ 96wk
event rate · per year
NCT03277261 · Phase 3 · combination
show 1 more result
0.091 vs 0.178 Teriflunomide per year @ 96wk
NCT03277248 · Phase 3 · combination
New and Enlarging T2 Lesion 0.213% (n=260) vs 2.789% (n=267) Teriflunomide @ 96wk
event count · % of participants
NCT03277261 · Phase 3 · combination
show 1 more result
0.282% (n=269) vs 2.831% (n=259) Teriflunomide
NCT03277248 · Phase 3 · combination
Time to CDP NA vs NA Teriflunomide months @ 96wk
time to event · months
NCT03277261 · Phase 3 · combination
show 1 more result
NA vs NA Teriflunomide months @ 96wk
NCT03277248 · Phase 3 · combination
NEDA 44.6% (n=271) vs 15% (n=274) Teriflunomide @ 96wk
responder rate · % of participants
NCT03277261 · Phase 3 · combination
show 1 more result
43% (n=272) vs 11.4% (n=272) Teriflunomide @ 96wk
NCT03277248 · Phase 3 · combination
Impaired SDMT 29.2% (n=271) vs 31.8% (n=274) Teriflunomide @ 96wk
responder rate · % of participants
NCT03277261 · Phase 3 · combination
show 1 more result
29% (n=272) vs 31.6% (n=272) Teriflunomide @ 96wk
NCT03277248 · Phase 3 · combination
Brain Volume -0.197% (n=204) vs -0.125% (n=207) Teriflunomide @ 96wk
percent change · % of baseline
NCT03277261 · Phase 3 · combination
show 1 more result
-0.194% (n=235) vs -0.176% (n=224) Teriflunomide @ 96wk
NCT03277248 · Phase 3 · combination
Gd-enhancing T1 Lesion 0.009% (n=272) vs 0.25% (n=267) Teriflunomide
event count · % of participants
NCT03277248 · Phase 3 · combination
New Gadolinium Enhancing T1 Lesion Count Per Scan 0 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 11 more results
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
New or Enlarging T2 Lesion 0.38 lesions @ 24wk
event count · lesions
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 11 more results
0.29 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.25 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.14 lesions @ 24wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.25 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 lesions @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
Annualized Relapse 0.28 per year @ 48wk
event rate · per year
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 5 more results
0 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.14 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0.14 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
0 per year @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
Relapse Free 75% (n=8) @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT02738775 · Phase 2 · registry result, not featured evidence
show 5 more results
100% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
100% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence
100% (n=8) @ 48wk
NCT02738775 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-281's landscape · Ublituximab's landscape